STARTSEITE
Impressum
Datenschutz
 
 
  SPOT ON
 

Rivaroxaban (XARELTO) now also approved for acute coronary syndrome

 
  NEW ON THE MARKET
 

Linaclotide (CONSTELLA) for irritable bowel syndrome with constipation

 
  THERAPY FROM A CRITICAL VIEWPOINT

Rheumatoid arthritis: biological versus classic DMARDs

 
  a-t READERS' QUESTIONS AND COMMENTS

Shortened antibiotic treatment due to rebate contract?

URO-VAXOM against recurrent urinary tract infection?

 
  IN BRIEF
 

First endpoint study with an incretin-based antidiabetic is negative

Now official: no codeine for children

Bone growth factor dibotermin alfa (INDUCTOS, INFUSE) - paid opinion leaders, ghostwriting, data manipulation and insufficient evidence of benefit

Medical sales representatives without control

Hydroxyl ethyl starch shall be withdrawn from the market

 
  CURRENT ADR NETWORK REPORT
 

Renal failure with gyrase inhibitors

 
  SIDE EFFECTS

The Federal Institute for Drugs and Medical Devices (BfArM) and FUMADERM (dimethyl fumarate and monoethyl fumarates): poor risk management

Finally: restrictions in the use of flupirtine (KATADOLON, generics)

 
  e a-t IN INTERNET
 

MUTAFLOR (E. coli Nissle) against sun allergy?

 

© arznei-telegramm 7/2013